|Videos|July 6, 2023
Recent Advances and Emerging Therapies in the Management of Alzheimer Disease
In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s disease. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.
Advertisement
0:00 Introduction
1:25 An overview of the current standard of care in of Alzheimer’s disease
4:55 Pathophysiology of Alzheimer’s disease
6:58 Aducanumab and lecanemab for Alzheimer’s disease
9:45 Mechanism of action of anti-amyloid agents
11:19 Leaky cell theory in Alzheimer's disease
12:35 Efficacy and safety of aducanumab and lecanemab
13:26 Safety of emerging agents in Alzheimer’s disease
16:37 Practical implementation of lecanemab
19:23 Challenges in CMS coverage for treatments of Alzheimer’s
24:05 Efficacy and safety of Donanemab
25:35 Overcoming clinical inertia around emerging agents in Alzheimer’s disease
29:30 A look into the future of management of Alzheimer’s disease
31:30 Summary
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5